menu
    • menu

    Company profile for Protagenic Therapeutics

    NEW Drugs in Dev: 2
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Protagenic Therapeutics, Inc. (OTCQB: PTIX) is a pre-clinical biopharmaceutical company endeavoring to develop first-in-class neuro-active peptides into human therapeutics to treat several stress related disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Protagenic TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1625th Ave, New York, New York, United States.
    Telephone
    Telephone
    213-260-4342
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://protagenic.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Protagenic Therapeutics Engages Regulatory and Strategy Partners
    Protagenic Therapeutics Engages Regulatory and Strategy Partners

    19 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-19/protagenic-therapeutics-engages-floyd-regulatory-strategic-consulting-as-regulatory-affairs-advisor

    PHARMIWEB
    19 May 2026
    Share Share
    Protagenic Therapeutics Names Bill Nichols Jr. President
    Protagenic Therapeutics Names Bill Nichols Jr. President

    23 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-23/protagenic-therapeutics-appoints-industry-veteran-bill-nichols-jr-as-president-to-accelerate-advanc

    PHARMIWEB
    23 Apr 2026
    Share Share
    Protagenic Therapeutics Moves To OTCQB Venture Market
    Protagenic Therapeutics Moves To OTCQB Venture Market

    10 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-10/protagenic-therapeutics-upgrades-from-otc-pink-to-otcqb-venture-market

    PHARMIWEB
    10 Mar 2026
    Share Share
    PT00114 Phase 1 Multiple-Dose Study Results
    PT00114 Phase 1 Multiple-Dose Study Results

    09 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-09/results-from-phase-1-multiple-dose-study-of-pt00114

    PHARMIWEB
    09 Dec 2025
    Share Share
    Protagenic Therapeutics Receives Nasdaq Non-Compliance Notice
    Protagenic Therapeutics Receives Nasdaq Non-Compliance Notice

    27 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-27/protagenic-therapeutics-announces-receipt-of-nasdaq-non-compliance-notice

    PHARMIWEB
    27 Nov 2025
    Share Share
    Protagenic Therapeutics Completes Phase 1 MAD Study Enrollment
    Protagenic Therapeutics Completes Phase 1 MAD Study Enrollment

    13 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-13/protagenic-therapeutics-announces-completion-of-enrollment-and-dosing-in-phase-1-mad-study

    PHARMIWEB
    13 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search